...
首页> 外文期刊>Oncology letters >Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma
【24h】

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

机译:细胞外基质金属蛋白酶诱导剂EMMPRIN / CD147在人骨肉瘤中的表达及其临床意义

获取原文
获取原文并翻译 | 示例
           

摘要

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Recent studies have shown that extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) promotes adhesion, invasion and metastasis of malignant tumor cells. The aim of this study was to investigate the impact of EMMPRIN/CD147 expression on prognosis and its correlation with clinicopathological characteristics in patients with osteosarcoma. The expression of EMMPRIN/CD147 in 55 surgical specimens from patients with osteosarcoma at stage IIA or above, 15 non-tumor rib bone tissues, three human osteosarcoma cell lines (Saos-2, U-2OS and MG-63), the human osteoblast cell line HOB and the malignant melanoma cell line A375 were examined by immunohistochemistry, western blot analysis and ELISA, respectively. The potential association of the levels of EMMPRIN/CD147 expression in osteosarcoma specimens with the overall survival of patients was statistically analyzed. We found that the EMMPRIN/CD147 was expressed in 45 out of 55 osteosarcomas, with immunoreactivity primarily within the membrane and cytoplasm of tumor cells, but not in the non-tumor bone tissues. We also observed that EMMPRIN/CD147 was expressed in Saos-2, U-2OS, MG-63 and A375, but not in HOB cells. The levels of EMMPRIN/CD147 expression correlated positively with the pathological degree of osteosarcoma and negatively with the survival period of patients with osteosarcoma. The expression of EMMPRIN/CD147 is a potential factor in the development and prognosis of ostcosarcoma and may be a novel therapeutic target of human ostcosarcoma.
机译:骨肉瘤是儿童和青少年中最常见的原发性恶性骨肿瘤。最近的研究表明,细胞外基质金属蛋白酶诱导剂(EMMPRIN / CD147)促进恶性肿瘤细胞的粘附,侵袭和转移。这项研究的目的是调查EMMPRIN / CD147表达对骨肉瘤患者预后的影响及其与临床病理特征的关系。 EMMPRIN / CD147在IIA级或以上,15例非肿瘤肋骨组织,三种人类骨肉瘤细胞系(Saos-2,U-2OS和MG-63),人类成骨细胞的55例外科手术标本中的表达分别通过免疫组织化学,Western印迹分析和ELISA检测了HOB细胞系和恶性黑色素瘤细胞A375。统计分析了骨肉瘤标本中EMMPRIN / CD147表达水平与患者总体生存率的潜在关联。我们发现EMMPRIN / CD147在55个骨肉瘤中的45个中表达,其免疫反应性主要在肿瘤细胞的膜和细胞质内,而在非肿瘤骨组织中不。我们还观察到EMMPRIN / CD147在Saos-2,U-2OS,MG-63和A375中表达,但在HOB细胞中不表达。 EMMPRIN / CD147表达水平与骨肉瘤的病理程度呈正相关,与骨肉瘤患者的生存期呈负相关。 EMMPRIN / CD147的表达是骨肉瘤发展和预后的潜在因素,可能是人类骨肉瘤的新型治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号